Sanofi in agreement with Janssen to develop E. coli the vaccine candidate information fournie par Reuters 03/10/2023 à 07:44
Le logo de Sanofi à Lyon
PARIS (Reuters) - Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.
Under the terms of the deal, both parties will co-fund current and future research and development costs. Sanofi will pay $175 million upfront to Janssen, followed by development and commercial milestones.
(Reporting by Tassilo Hummel; Editing by Benoit Van Overstraeten)